Cancer testing firm names chief scientific officer

FORT MYERS — NeoGenomics, a leading provider of cancer-focused genetic testing services, named Dr. Lawrence Weiss chief scientific officer. Weiss has served as medical director and laboratory director for NeoGenomics Laboratories since joining NeoGenomics as part of its acquisition of Clarient in 2015.

“Larry is a highly regarded thought leader in the oncology and pathology community, with years of medical and scientific leadership experience at NeoGenomics and other organizations,” says NeoGenomics Chairman and CEO Douglas VanOort in a statement. “Dr. Weiss is responsible for driving NeoGenomics scientific innovation initiatives and advancing our reputation in the oncology diagnostics community.”